UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 1, 2011
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
|
DELAWARE
|
000-51436
|
20-2903526
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
248 Route
25A, No. 2
East
Setauket, New York 11733
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: 631 942 7959
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (See General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17
CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
8.01.
|
Other
Events
|
On
February 1, 2011, the Company received from the Internal Revenue Service a
payment of $116,485.25 representing the final payment under a grant relating to
a qualifying investment in a
therapeutic discovery project under Section 48D of the Internal Revenue Code for
the Company’s LB-1 compound.. The initial payment of $127,994 under the
grant was received in November 2010.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. | |||
|
Date: February
17, 2011
|
By:
|
/s/ John S. Kovach | |
|
John
S. Kovach, Chief Executive Officer
|
|||
2